Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
The Standard-Times on MSN10h
New Bedford family of toddler fighting leukemia gets support from Cops for Kids with CancerCops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...
NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...
JonesResearch upgraded IN8bio (INAB) to Buy from Hold with a $1.20 price target The stock in morning trading is up 26%, or 7c, to 34c. The ...
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.
HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback